FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   PreferencesPreferences   Log in to check your private messagesLog in to check your private messages   Log inLog in 
Forum index » Medicine forums » laboratory
IMPROVED NANOBACTERIA TESTS
Post new topic   Reply to topic Page 1 of 1 [3 Posts] View previous topic :: View next topic
Author Message
NanoBiotech Reviews
medicine forum beginner


Joined: 09 Jun 2005
Posts: 22

PostPosted: Wed Oct 26, 2005 4:18 pm    Post subject: IMPROVED NANOBACTERIA TESTS Reply with quote

Nanobac Introduces New Improved ELISA Kits for Detection of Calcifying
Nano-Particles, also known as Nanobacteria
10/26/2005 8:00:00 AM EST
Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company")
announced today the introduction of two new versions of its
NANOCAPTURE(TM) and NANO-SERO(TM) ELISA test kits for the detection of
Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum
or plasma. The new kits offer improved sensitivity, lower background
and improved stability over the previous versions. Nanobac has added
new standards to improve precision at the low end and freeze dried the
critical components for improved stability.
"Our demand for CNP diagnostic products is increasing as CNP's or
nanobacteria are implicated in more and more chronic diseases," stated
Grant Carlson, Nanobac's President and Chief Operating Officer.
"Nanobac has worked hard to develop robust, sensitive and reproducible
ELISA test kits for the CNP/nanobacteria research community. These kits
are CE marked and ready for immediate shipment throughout the European
Union. In the United States the kits will be sold For Research Use Only
(RUO)."
The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the
quantitative measurement of CNP/nanobacterial antigen in serum or
plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay
for the quantitative measurement of anti-CNP antibodies in serum or
plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test
kits at the world's #1 medical trade show, MEDICA, in Dusseldorf,
Germany, November 16-19, 2005. Last year the show attracted 136,000
visitors from around the world. Nanobac intends to meet with potential
customers and establish its global network of in vitro diagnostic
distributors.
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is a broad-based life science company that
discovers, develops, manufactures, and markets a range of products and
services to improve people's health through the detection and treatment
of Calcifying Nano-Particles, otherwise known as "nanobacteria". The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in soft tissue calcification, particularly in coronary
artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
reagents for the detection of Calcifying Nano-Particles. IVD products
include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
Nano-Vision(TM) line of antibodies and reagents. Nanobac's
BioAnalytical Services works with biopharmaceutical partners to develop
and apply methods for avoiding, detecting, and inactivating or
eliminating CNPs from raw materials. Nanobac's Drug Discovery and
Development efforts are focused on developing new and existing
compounds that effectively inhibit, destroy or neutralize CNPs. The
Company also markets Dietary Supplements through its subsidiary,
Nanobac Sciences, LLC.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and some
oral statements of Nanobac Life Sciences, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects,"
and similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Life Sciences, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by
such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes that
the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Life Sciences, Inc. has no specific intention to update
these statements.
CONTACT:
Nanobac Life Sciences, Inc. John Stanton, CEO or Grant Carlson,
President/COO
Telephone: (813) 264-2241
Website: www.nanobaclabs.com
Back to top
pedrop
medicine forum beginner


Joined: 20 Apr 2005
Posts: 7

PostPosted: Thu Nov 17, 2005 8:06 am    Post subject: R: IMPROVED NANOBACTERIA TESTS Reply with quote

What about nanobacteria and autoimmune deseases such as LES, SS, CREST ?

NanoBiotech Reviews <gmezo@nanobiotech.us> wrote in message
1130343534.445783.203080@g49g2000cwa.googlegroups.com...
Quote:
Nanobac Introduces New Improved ELISA Kits for Detection of Calcifying
Nano-Particles, also known as Nanobacteria
10/26/2005 8:00:00 AM EST
Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company")
announced today the introduction of two new versions of its
NANOCAPTURE(TM) and NANO-SERO(TM) ELISA test kits for the detection of
Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum
or plasma. The new kits offer improved sensitivity, lower background
and improved stability over the previous versions. Nanobac has added
new standards to improve precision at the low end and freeze dried the
critical components for improved stability.
"Our demand for CNP diagnostic products is increasing as CNP's or
nanobacteria are implicated in more and more chronic diseases," stated
Grant Carlson, Nanobac's President and Chief Operating Officer.
"Nanobac has worked hard to develop robust, sensitive and reproducible
ELISA test kits for the CNP/nanobacteria research community. These kits
are CE marked and ready for immediate shipment throughout the European
Union. In the United States the kits will be sold For Research Use Only
(RUO)."
The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the
quantitative measurement of CNP/nanobacterial antigen in serum or
plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay
for the quantitative measurement of anti-CNP antibodies in serum or
plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test
kits at the world's #1 medical trade show, MEDICA, in Dusseldorf,
Germany, November 16-19, 2005. Last year the show attracted 136,000
visitors from around the world. Nanobac intends to meet with potential
customers and establish its global network of in vitro diagnostic
distributors.
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is a broad-based life science company that
discovers, develops, manufactures, and markets a range of products and
services to improve people's health through the detection and treatment
of Calcifying Nano-Particles, otherwise known as "nanobacteria". The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in soft tissue calcification, particularly in coronary
artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
reagents for the detection of Calcifying Nano-Particles. IVD products
include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
Nano-Vision(TM) line of antibodies and reagents. Nanobac's
BioAnalytical Services works with biopharmaceutical partners to develop
and apply methods for avoiding, detecting, and inactivating or
eliminating CNPs from raw materials. Nanobac's Drug Discovery and
Development efforts are focused on developing new and existing
compounds that effectively inhibit, destroy or neutralize CNPs. The
Company also markets Dietary Supplements through its subsidiary,
Nanobac Sciences, LLC.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and some
oral statements of Nanobac Life Sciences, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects,"
and similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Life Sciences, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by
such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes that
the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Life Sciences, Inc. has no specific intention to update
these statements.
CONTACT:
Nanobac Life Sciences, Inc. John Stanton, CEO or Grant Carlson,
President/COO
Telephone: (813) 264-2241
Website: www.nanobaclabs.com

Back to top
NanoBiotech Reviews
medicine forum beginner


Joined: 09 Jun 2005
Posts: 22

PostPosted: Thu Nov 17, 2005 5:07 pm    Post subject: Re: R: IMPROVED NANOBACTERIA TESTS Reply with quote

According to inside sources, persons with LES, SS and CREST have
UNUSUALLY high titers for positivity on Nanobacteria antigen and
antibody tests. Physicians that prescribed the nanobiotic, NanobacTX
for heart disease (coronary artery disease) patients saw clinical
improvement in heart disease symptoms as well as improvement in LES, SS
and CREST symptoms (nanobacteria titers and inflammatory titers).
Nanobac has not started formal studies for LE, SS or CREST yet due to
funding. But if YOU are a sufferer of LE, SS or CREST, all is not
lost......Nanobac Life Sciences ( www.nanobaclabs.com ) has an OTC
version of their nanobiotic available now, without prescription. In
order to get the appropriate results as in the clinical trials, a
generic tetracycline 500mg capsule must be taken every night with the
Nanobac regimen. Yes, the skeptics are out there.....but those that
have tried the regimen have been UNIVERSALLY PLEASED with the
improvements. Talk to your doctor.
Back to top
Google

Back to top
Display posts from previous:   
Post new topic   Reply to topic Page 1 of 1 [3 Posts] View previous topic :: View next topic
The time now is Thu Jan 08, 2009 12:42 am | All times are GMT
Forum index » Medicine forums » laboratory
Jump to:  

Similar Topics
Topic Author Forum Replies Last Post
No new posts Otis is right! The plus lens improved... acemanvx@yahoo.com vision 19 Sat Jul 08, 2006 8:26 am
No new posts Tests for mumps prove unreliable john nursing 0 Fri Jul 07, 2006 9:35 pm
No new posts CLIA waived tests res laboratory 6 Wed Jun 14, 2006 6:58 am
No new posts Stress tests - inaccurate R. Pierce Butler cardiology 8 Sat May 13, 2006 8:41 pm
No new posts Unproved Lyme Disease Tests Prompt Wa... Georgia lyme 0 Sat May 13, 2006 12:28 pm

Credit Card Advice | Credit Card Consolidation | Compare Credit Cards | Credit Counseling | Debt Consolidation
Copyright © 2004-2005 DeniX Solutions SRL
Other DeniX Solutions sites: electronics forum, Science forum Unix/Linux blog Unix/Linux documentation Unix/Linux forums


Powered by phpBB © 2001, 2005 phpBB Group
[ Time: 0.2381s ][ Queries: 16 (0.1402s) ][ GZIP on - Debug on ]